

Appendix O: Clinical evidence – forest plots and summary ROC curves for all studies

Appendix O:	Clinical evidence – forest plots and summary ROC curves for all studies	1
0.1	Assessment tools.....	6
0.1.1	Tools for the recognition of mental health problems	6
0.1.2	Risk assessment tools.....	15
0.1.2.1	VISCI for assessment of risk of sexual re-offending	15
0.2	Interventions for staff training.....	16
0.2.1	Organisational linkage intervention (OLI) plus Medication-assisted training (MAT) vs Training alone at post-treatment	16
0.3	Interventions for promoting mental health and well being.....	17
0.3.1	Parent training for parent-child attachment versus treatment as usual for women with sub-threshold symptoms at post-treatment.....	17
0.3.2	Yoga for promoting mental health and wellbeing versus waiting list control.....	20
0.3.3	Meditation for promoting mental health and well-being versus treatment as usual.....	21
0.3.4	Physical exercise programmes for promoting mental health and well-being versus exercise as usual at post-treatment	22
0.4	Interventions for substance misuse.....	23
0.4.1	Psychological interventions	23
0.4.1.1	CBT versus active intervention	23
0.4.1.2	CBT versus wait-list control	25
0.4.1.3	ACT versus CBT	25
0.4.1.4	ACT versus waitlist	26
0.4.1.5	Mindfulness-based relapse prevention (MBRP) versus active intervention .	27
0.4.1.6	Contingency management versus active intervention at post-treatment	28
0.4.1.7	Contingency management versus control at post-treatment.....	29
0.4.1.8	Motivational enhancement therapy versus active intervention	29
0.4.1.9	Motivational interviewing or feedback versus control or treatment as usual.....	31
0.4.1.10	Group counselling versus treatment as usual	33
0.4.1.11	Self-help versus control.....	34
0.4.2	Pharmacological interventions	35
0.4.2.1	Naloxone versus placebo	35
0.4.2.2	Naltrexone versus active intervention	35
0.4.2.3	Methadone versus waitlist control	39
0.4.2.4	Alpha-adrenergic agonists versus opioid maintenance	41

O.4.2.5	Opioid substitution versus active intervention	42
O.4.3	Combined psychological and pharmacological interventions.....	44
O.4.3.1	Antidepressants plus psychological therapy versus psychological therapy alone for substance misuse.....	44
O.4.4	Support and educational interventions	44
O.4.4.1	Psychoeducation versus control or treatment as usual.....	44
O.4.4.2	Employment workshop versus control or treatment as usual	45
O.4.5	Physical interventions	45
O.4.5.1	Acupuncture versus active intervention.....	45
O.5	Interventions for ‘other’ mental health disorders.....	46
O.5.1	Depression.....	46
O.5.1.1	Psychotherapy vs PSYCHOED.....	46
O.5.1.2	Group therapy vs Individual therapy	46
O.5.1.3	Arts-based Therapy vs TAU.....	47
O.5.2	Vulnerable inmates with suicidal risks	48
O.5.2.1	Social problem solving group vs No treatment control.....	48
O.5.3	Anxiety disorder	49
O.5.3.1	Self-help therapy vs Wait-list control.....	49
O.5.4	PTSD	50
O.5.4.1	Psychotherapy vs Control	50
O.5.4.2	TIR vs Wait-list control.....	50
O.5.4.3	TARGET vs SGT	51
O.5.4.4	Focused group therapy vs Wait-list control	52
O.5.4.5	Group Therapy vs No contact control	52
O.5.5	ADHD.....	53
O.5.5.1	MPH vs Placebo.....	53
O.5.6	Antisocial personality disorders	53
O.5.6.1	Tiagabine vs Placebo	53
O.5.7	Severe Mental Illness	54
O.5.7.1	IM Paliperidone vs Oral Antipsychotics for schizophrenia	54
O.5.7.2	The Citizenship Project vs TAU.....	54
O.5.7.3	IPS vs Peer Support	55
O.5.8	Uncategorized mental health disorders.....	56
O.5.8.1	Parenting from inside (PFI) vs TAU.....	56
O.5.8.2	Music therapy vs Standard care for mental health disorders	56
O.5.8.3	Music therapy vs Wait-list control for antisocial personality disorders.....	57
O.6	Interventions for paraphilic disorders	58
O.6.1	MPA + psych intervention vs psych intervention only at post-treatment	58
O.6.2	MPA only vs psych intervention only at post-treatment	59

O.6.3	Psychoeducational interventions, principally CBT-informed psychoeducation (including SOTP) versus treatment as usual, no treatment or waitlist control for paraphilic disorders.....	59
O.6.4	Reintegration programmes versus treatment as usual for paraphilic disorders.....	63
O.6.5	Imaginal desensitization plus MPA versus MPA for paraphilic disorders	65
O.6.6	Imaginal desensitization versus covert sensitization for paraphilic disorders.....	65
O.7	Service delivery models.....	66
O.7.1	Street Triage (Before versus After)	66
O.7.2	Diversion Services	67
O.7.2.1	Before and After Diversion Services.....	67
O.7.2.2	Assessment versus No assessment at court.....	67
O.7.2.3	Court Diversion vs Community Diversion	68
O.7.3	Patient Navigation Intervention versus facilitated enrolment (at 26-weeks follow-up).....	69
O.7.4	Neighbourhood outreach (Before versus After).....	69
O.7.5	Drug Rehabilitation Program versus TAU	70
O.7.6	Case management.....	70
O.7.6.1	Case management vs TAU for substance misuse disorders	70
O.7.6.2	Case management vs active intervention for substance misuse disorders .	75
O.7.6.3	Assertive Community Treatment vs TAU for substance misuse disorders ..	77
O.7.6.4	Case management vs TAU for mental health disorders other than substance misuse	78
O.7.7	Drug court.....	79
O.7.7.1	Drug court vs TAU.....	79
O.7.7.2	Drug court vs active intervention.....	79
O.7.8	Opioid substitution therapy.....	81
O.7.8.1	Opioid substitution therapy + case management vs active intervention	81
O.7.9	Automated Telephony (AT) with feedback versus AT alone	83
O.7.10	IDDT versus TAU	85
O.7.11	Housing First versus TAU.....	85
O.7.12	TIMA versus TAU.....	86
O.7.13	Service Brokerage Intervention versus TAU	86
O.7.14	Therapeutic communities	87
O.7.14.1	Therapeutic community versus waitlist control.....	87
O.7.14.2	Therapeutic community versus active intervention.....	87
O.7.14.3	Modified therapeutic community versus psychoeducation	90
O.7.14.4	Enhanced therapeutic community versus standard therapeutic community	91
O.7.14.5	Gender-responsive therapeutic community versus standard therapeutic community	92
O.7.14.6	Gender-specific therapeutic community versus psychoeducation	94

O.7.14.7 Re-entry modified therapeutic community versus treatment as usual..... 97

Abbreviations

ABCS	Abel and Becker Cognitions Scale
ACT	acceptance and commitment therapy
APQ	Alabama Parenting Questionnaire
ASI-6	Addiction Severity Index-6
BDI	Beck Depression Inventory
BSI	Brief Symptom Inventory
CBT	cognitive behavioural therapy
CES-D	Centre for Epidemiological Studies Depression scale
CIB	Coding Interactive Behaviour scales
CJS	criminal justice system
CMHS (-M/W)	Correctional Mental Health Screen (for Men/Women)
ECBI	Eyberg Child Behaviour Inventory
HELP-PC	
MORS	Mother's Object Relations Scale
MPA	medroxyprogesterone acetate
PANAS	Positive and Negative Affect Scale
PDI	Parent Development Interview
PSS	Perceived Stress Scale
RDS	Referral Decision Scale
ROC	receiver operating characteristic
RCT	randomised controlled trial
SCL-90-R	Symptom Checklist-90-Revised
SIP	Short Inventory of Problems
SOR	sex offender's register
SOTP	sex offender treatment programme
VISCI	Viennese Instrument for Suicidality in Correctional Institutions

O.1 Assessment tools

O.1.1 Tools for the recognition of mental health problems

Figure 1: Sensitivity and specificity of index tests for the recognition of depression




Figure 2: Summary ROC curves for the index tests for depression




Figure 3: Sensitivity and specificity of the RDS for the recognition of bipolar disorder

Referral Decision Scale (RDS): Bipolar Subscale - Cut-off 1

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Teplin 1989a	24	92	0	612	1.00 [0.86, 1.00]	0.87 [0.84, 0.89]		

Referral Decision Scale (RDS): Bipolar Subscale - Cut-off 2

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Teplin 1989a	22	14	2	690	0.92 [0.73, 0.99]	0.98 [0.97, 0.99]		

Referral Decision Scale (RDS): Bipolar Subscale - Cut-off 3

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Teplin 1989a	20	0	4	704	0.83 [0.63, 0.95]	1.00 [0.99, 1.00]		

Figure 4: Summary ROC curves for the RDS for bipolar disorder




Figure 5: Sensitivity and specificity of index tests for the recognition of affective disorder

Correctional Mental Health Screen for Men (CMHS-M) - Cut-off 7 - All Men

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ford 2007	20	48	4	129	0.83 [0.63, 0.95]	0.73 [0.66, 0.79]		

Correctional Mental Health Screen for Men (CMHS-M) - Cut-off 7 - Caucasian Men

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ford 2007	17	18	1	62	0.94 [0.73, 1.00]	0.78 [0.67, 0.86]		

Correctional Mental Health Screen for Men (CMHS-M) - Cut-off 7 - Black Men

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ford 2007	3	20	0	46	1.00 [0.29, 1.00]	0.70 [0.57, 0.80]		

Correctional Mental Health Screen for Women (CMHS-W) - Cut-off 5

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ford 2007	24	20	9	47	0.73 [0.54, 0.87]	0.70 [0.58, 0.81]		

Figure 6: Summary ROC curves for the index tests for affective disorder




Figure 7: Sensitivity and specificity of the HELP-PC (cut-off 1) for the recognition of learning disabilities

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
McKinnon 2015	5	41	1	304	0.83 [0.36, 1.00]	0.88 [0.84, 0.91]		

Figure 8: Summary ROC curve for the HELP-PC for learning disabilities




Figure 9: Sensitivity and specificity of RDS: schizophrenia subscale (cut-off 1) for the recognition of schizophrenia

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Teplin 1989a	21	28	3	676	0.88 [0.68, 0.97]	0.96 [0.94, 0.97]		

Figure 10: Summary ROC curve for the RDS: schizophrenia subscale for schizophrenia




Figure 11: Sensitivity and specificity of the HELP-PC (cut-off not reported) for the recognition of psychosis

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
McKinnon 2014	26	55	2	240	0.93 [0.76, 0.99]	0.81 [0.76, 0.86]		

Figure 12: Summary ROC curve for the HELP-PC for psychosis




Figure 13: Sensitivity and specificity of the CMHS-W (cut-off 4) for the recognition of Axis-I or Axis-II disorder

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ford 2009	51	5	17	27	0.75 [0.63, 0.85]	0.84 [0.67, 0.95]		

Figure 14: Summary of ROC curve for the CMHS-W for Axis-I or Axis-II disorder




Figure 15: Sensitivity and specificity of index tests for the recognition of Axis-I or Axis-II disorder excluding Anti-Social Personality Disorder

Correctional Mental Health Screen for Men (CMHS-M) - Cut-off 5

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ford 2009	37	13	9	47	0.80 [0.66, 0.91]	0.78 [0.66, 0.88]		

Correctional Mental Health Screen for Men (CMHS-M) - Cut-off 6

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ford 2007	51	33	18	99	0.74 [0.62, 0.84]	0.75 [0.67, 0.82]		
Ford 2009	32	10	14	50	0.70 [0.54, 0.82]	0.83 [0.71, 0.92]		

Correctional Mental Health Screen for Men (CMHS-M) - Cut off 6 - Caucasian Men

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ford 2007	27	14	6	50	0.82 [0.65, 0.93]	0.78 [0.66, 0.87]		

Correctional Mental Health Screen for Men (CMHS-M) - Cut-off 6 - Black Men

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ford 2007	16	14	4	35	0.80 [0.56, 0.94]	0.71 [0.57, 0.83]		

Correctional Mental Health Screen for Women (CMHS-W) - Cut-off 4

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ford 2009	45	11	16	28	0.74 [0.61, 0.84]	0.72 [0.55, 0.85]		

Referral Decision Scale (RDS) - Cut-off 3

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ford 2007	11	2	4	10	0.73 [0.45, 0.92]	0.83 [0.52, 0.98]		

Figure 16: Summary ROC curves for the index tests for Axis-I or Axis-II disorder excluding Anti-Social Personality Disorder





Figure 17: Sensitivity and specificity of the current prison reception health screen (cut-off 1) for the recognition of serious mental illness

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Grubin 2002	29	20	1	100	0.97 [0.83, 1.00]	0.83 [0.75, 0.90]		

Figure 18: Summary of ROC curve for the current prison reception health screen for serious mental illness



O.1.2 Risk assessment tools

O.1.2.1 VISCI for assessment of risk of sexual re-offending

Figure 19: VISCI using a cut-off of 3.38

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Frottier 2009	18	9	7	41	0.72 [0.51, 0.88]	0.82 [0.69, 0.91]		

O.2 Interventions for staff training

O.2.1 Organisational linkage intervention (OLI) plus Medication-assisted training (MAT) vs Training alone at post-treatment

Figure 20 Familiarity with medication: Methadone




Figure 21 Referral knowledge: Methadone




Figure 22 Intent to refer clients to MAT: Methadone




Figure 23 Overall perception and knowledge: Methadone




Figure 24 Familiarity with the medication: Buprenorphine




Figure 25 Referral knowledge: Buprenorphine




Figure 26 Intent to refer clients to MAT: Buprenorphine





Figure 27 Overall perception and knowledge: Buprenorphine



Note – The scores ranged from 1 (strongly disagree) to 5 (strongly agree).

O.3 Interventions for promoting mental health and well being

O.3.1 Parent training for parent-child attachment versus treatment as usual for women with sub-threshold symptoms at post-treatment

Figure 28: Mean symptoms of depression as measured by the Center for Epidemiological Studies Depression Scale (CES-D)




Figure 29: Number of participants with symptoms of depression (CES-D=>16)




Figure 30: Mother-child attachment/interaction (after 4 week treatment): mean scores on the Reflective Functioning subscale of the Parent Development Interview (PDI)




Figure 31: Mother-child attachment/interaction (after 4 week treatment): mean scores for dyadic attunement based on behavioural observation of mother-

infant interaction during free-play coded using Coding Interactive Behaviour (CIB) scales




Figure 32: Maternal perceptions of child (after 4 week treatment): mean scores for positive perceptions of the infant as measured by the Mother’s Object Relations Scale (MORS), Warmth subscale




Figure 33: Maternal perceptions of child (after 4 week treatment): mean scores for negative perceptions of the infant as measured by the MORS, Invasion subscale




Figure 34: Maternal perceptions of child (after 30 week treatment): mean scores for parental reports of the intensity of children’s problem behaviour as measured by the Eyberg Child Behavior Inventory (ECBI)




Figure 35: Maternal perceptions of child (after 30 week treatment): mean scores for the extent to which child behaviour is a problem for parents as measured by the ECBI




Figure 36: Maternal perceptions of child (after 30 week treatment): mean scores for maternal perceptions of their involvement with their child as measured by the Alabama Parenting Questionnaire (APQ), Involvement subscale




Figure 37: Maternal perceptions of child (after 30 week treatment): mean scores for maternal perceptions of their positive parenting as measured by the APQ, Positive parenting subscale




Figure 38: Maternal perceptions of child (after 30 week treatment): mean scores for maternal perceptions of their poor monitoring/supervision as measured by the APQ, Poor monitoring/supervision subscale




Figure 39: Maternal perceptions of child (after 30 week treatment): mean scores for maternal perceptions of their inconsistent discipline as measured by the APQ, Inconsistent discipline subscale




Figure 40: Maternal perceptions of child (after 30 week treatment): mean scores for maternal perceptions of their corporal punishment as measured by the APQ, Corporal punishment subscale





Figure 41: Drop out before the post-intervention assessment



0.3.2 Yoga for promoting mental health and wellbeing versus waiting list control

Figure 42: Positive and negative affect (after 10 week treatment): mean scores of positive affect as measured by the Positive and Negative Affect Scale (PANAS)




Figure 43: Positive and negative affect (after 10 week treatment): mean scores of negative affect as measured by the PANAS




Figure 44: Stress (after 10 week treatment): mean scores on the Perceived Stress Scale (PSS)




Figure 45: Psychological distress (after 10 week treatment): mean scores on the Brief Symptom Inventory (BSI)





Figure 46: Drop-out (after 10 week treatment): number of participants who dropped out before the post-intervention assessment



O.3.3 Meditation for promoting mental health and well-being versus treatment as usual

Figure 47: Desire to throw things/hit people (after 7 week treatment): mean scores on study-specific measure within past month




Figure 48 Being bothered by nail biting (after 7 week treatment): mean scores on study-specific measure within past month




Figure 49: Feelings of guilt (after 7 week treatment): mean scores on study-specific measure within past month




Figure 50 Feelings of hopelessness (after 7 week treatment): mean scores on study-specific measure within past month





Figure 51: Being bothered by sleep difficulties (after 7 week treatment): mean scores on study-specific measure within past month



O.3.4 Physical exercise programmes for promoting mental health and well-being versus exercise as usual at post-treatment

Figure 52: Change in Symptom Checklist-90-Revised (SCL-90-R) Global Severity Index (GSI)




Figure 53: Change in Symptom Checklist-90-Revised (SCL-90-R) Positive Symptom Total (PST)





Figure 54: Change in Symptom Checklist-90-Revised (SCL-90-R) Positive Symptom Distress Index (PSDI)



O.4 Interventions for substance misuse

O.4.1 Psychological interventions

O.4.1.1 CBT versus active intervention

Figure 55: Days using cannabis during treatment




Figure 56: Days with a positive urine test during treatment




Figure 57: Days with a positive breathalyser test during treatment




Figure 58: Days abstinent during treatment




Figure 59: Addiction Severity Index (ASI-6): alcohol composite score at 26-38 weeks follow-up




Figure 60: Addiction Severity Index (ASI-6): drug composite score at 26-38 weeks follow-up




Figure 61: Weeks abstinent (3 month follow-up) at 26-38 weeks follow-up





Figure 62: Re-incarceration at 26-38 weeks follow-up



O.4.1.2 CBT versus wait-list control

Figure 63: Addiction Severity Index (ASI-6) : alcohol composite score at post-treatment




Figure 64: Addiction Severity Index (ASI-6): drug composite score at post-treatment





Figure 65: Abstinent in previous 3 months (6 month follow-up)



O.4.1.3 ACT versus CBT

Figure 66: Addiction Severity Index (ASI-6): alcohol composite score at post-treatment




Figure 67: Addiction Severity Index (ASI-6): drug composite score at post-treatment





Figure 68: Abstinent from drugs in previous 3 months at post-treatment



0.4.1.4 ACT versus waitlist

Figure 69: Addiction Severity Index (ASI-6): alcohol composite score at 42 weeks follow-up




Figure 70: Addiction Severity Index (ASI-6): drug composite score at 42 weeks follow-up





Figure 71: Abstinent from drugs in previous 3 months at 42 weeks follow-up



O.4.1.5 Mindfulness-based relapse prevention (MBRP) versus active intervention

Figure 72: Drug-use days at post-treatment




Figure 73: Short Inventory of Problems (SIP) follow-up at post-treatment





Figure 74: Addiction Severity Index (ASI-6) at post-treatment



0.4.1.6 Contingency management versus active intervention at post-treatment

Figure 75: Days using cannabis during treatment




Figure 76: Addiction Severity Index (ASI-6): marijuana composite score at post-treatment




Figure 77: Days cannabis use per month at post-treatment




Figure 78: Participants still in treatment at follow-up at post-treatment






Figure 79: Number of days in treatment at post-treatment



0.4.1.7 Contingency management versus control at post-treatment

Figure 80: Arrests for public drunkenness



0.4.1.8 Motivational enhancement therapy versus active intervention

Figure 81: Percentage of days abstinent from alcohol (self-report) at post-treatment




Figure 82: Percentage of days abstinent from alcohol and drugs at post-treatment




Figure 83: Drinks per drinking days at post-treatment




Figure 84: Percentage of days with cannabis use during treatment




Figure 85: Percentage of urine tests positive for cannabis use during treatment





Figure 86: Self-reported motivation to take steps to change substance abuse scores at post-treatment



O.4.1.9 Motivational interviewing or feedback versus control or treatment as usual

Figure 87: Self-reported drug use at post-treatment




Figure 88: Self-reported days with drug use in the past 30 days (10 month follow-up)




Figure 89: Urine test positive for drug use during study period at post-treatment




Figure 90: Self-reported alcohol use at post-treatment




Figure 91: Days with illegal activity in the past 30 days (10 month follow-up)




Figure 92: Drop-out from subsequent treatment (binge drinking group) at post-treatment




Figure 93: Drop-out from subsequent treatment (non-binge drinking group) at post-treatment




Figure 94: Number of subsequent treatment sessions attended (binge drinking group) at post-treatment




Figure 95: Number of subsequent treatment sessions attended (non-binge drinking group) at post-treatment





Figure 96: Specialty addiction clinic attendance at post-treatment



O.4.1.10 Group counselling versus treatment as usual

Figure 97: Re-arrest (12 month follow-up)




Figure 98: Number of reconvictions (12 month follow-up)




Figure 99: Re-incarceration (12 month follow-up)




Figure 100: Days incarcerated (12 month follow-up)






Figure 101: Self-reported drug use (12 month follow-up)



O.4.1.11 Self-help versus control

Figure 102: Subsequent bookings (12 month follow-up)



O.4.2 Pharmacological interventions

O.4.2.1 Naloxone versus placebo

Figure 103: Discontinued medication at post-treatment





Figure 104: Number of urine test positive at post-treatment



O.4.2.2 Naltrexone versus active intervention

Figure 105: Retained in treatment at post-treatment




Figure 106: Urine test positive for drugs at post-treatment




Figure 107: Cocaine use at post-treatment




Figure 108: Opioid use post-treatment




Figure 109: Injection drug use post-treatment




Figure 110: Days of drug use per month (6-month follow-up)




Figure 111: Re-incarceration at post-treatment




Figure 112: Parole violations at post-treatment




Figure 113: Drug charges at post-treatment




Figure 114: Days of criminal activity per month (6 month follow-up)





Figure 115: Adverse events (12-month follow-up)



O.4.2.3 Methadone versus waitlist control

Figure 116: Drop-out at post-treatment




Figure 117: Positive for opioids at post-treatment




Figure 118: Re-incarceration at 4-year follow-up




Figure 119: Adverse events (1-month follow-up)




Figure 120: Number of participants in contact with MH/substance misuse services (1-month follow-up)






Figure 121: Any drug use (1-month follow-up)



0.4.2.4 Alpha-adrenergic agonists versus opioid maintenance

Figure 122: Total withdrawal symptoms at post-treatment



0.4.2.5 Opioid substitution versus active intervention

Figure 123: Drop-out at post-treatment




Figure 124: Abstinence at post-treatment




Figure 125: Opioid abuse (3 month follow-up)




Figure 126: Self-reported injection drug use at post-treatment




Figure 127: Number of times re-arrested (3 month follow-up)




Figure 128: Re-arrest for drug crimes (3 month follow-up)





Figure 129: Re-incarceration at post-treatment



O.4.3 Combined psychological and pharmacological interventions

O.4.3.1 Antidepressants plus psychological therapy versus psychological therapy alone for substance misuse

Figure 130: Number of participants who failed to complete treatment at post-treatment




Figure 131: Spielberger State Anxiety Inventory score at post-treatment






Figure 132: Hamilton Depression Rating Scale score at post-treatment



O.4.4 Support and educational interventions

O.4.4.1 Psychoeducation versus control or treatment as usual

Figure 133: Number of days with uncontrolled drinking at post-treatment



0.4.4.2 Employment workshop versus control or treatment as usual

Figure 134: Number of participants employed at post-treatment





Figure 135: Days in paid employment at post-treatment



0.4.5 Physical interventions

0.4.5.1 Acupuncture versus active intervention

Figure 136: Drop-out at post-treatment





Figure 137: Urine test positive for drug use at post-treatment



O.5 Interventions for ‘other’ mental health disorders

O.5.1 Depression

O.5.1.1 Psychotherapy vs PSYCHOED

Figure 138: Depression by HRSD scales (at post-treatment)





Figure 139: Depression by HRSD scales at 13-weeks follow-up



O.5.1.2 Group therapy vs Individual therapy

Figure 140: Depression by BDI scales at post-treatment




Figure 141: Depression by Hopeless scale at post-treatment




Figure 142: Depression by MMPI D scale at post-treatment




Figure 143: Depression by MMPI D scale at 39-weeks follow-up





Figure 144: Depression by Multiple affect adjective checklist D scale at post-treatment



0.5.1.3 Arts-based Therapy vs TAU

Figure 145: Change in Adult Nowicki-Strickland Locus of Control Scale (ANS) at post-treatment




Figure 146: Change in Beck Depression Inventory (BDI): Total at post-treatment




Figure 147: Change in formal elements of arts therapy scale rating guide (FEATS): Prominence of colour at post-treatment





Figure 148: Change in formal elements of arts therapy scale rating guide (FEATS): Colour Fit at post-treatment



0.5.2 Vulnerable inmates with suicidal risks

0.5.2.1 Social problem solving group vs No treatment control

Figure 149: Depression by HADS scales at post-treatment




Figure 150: Anxiety by HADS scales at post-treatment




Figure 151: Depression by Beck Hopeless scales at post-treatment




Figure 152: Decision making ability by SPSI:R scales at post-treatment




Figure 153: Depression by HADS scales at 13-weeks follow-up




Figure 154: Anxiety by HADS scales at 13-weeks follow-up





Figure 155: Depression by Beck Hopeless scales (13 weeks follow-up)



0.5.3 Anxiety disorder

0.5.3.1 Self-help therapy vs Wait-list control

Figure 156: Anxiety by HADS scales at post-treatment






Figure 157: Anxiety by HADS scales at 4-weeks follow-up



0.5.4 PTSD

0.5.4.1 Psychotherapy vs Control

Figure 158: Trauma by TSI at post-treatment



0.5.4.2 TIR vs Wait-list control

Figure 159: Depression by BDI scales at post-treatment




Figure 160: Depression by BDI scales at 13 weeks follow-up




Figure 161: PTSD by PSS scales at post-treatment




Figure 162: PTSD by PSS scales (13 weeks follow-up)




Figure 163: Generalized Expectancy by Success scale at post-treatment




Figure 164: Generalized Expectancy for Success scales at 13-weeks follow-up




Figure 165: Clinical anxiety scales at post-treatment





Figure 166: Clinical anxiety scales at 13-weeks follow-up at post-treatment



O.5.4.3 TARGET vs SGT

Figure 167: PTSD symptoms by CAPS scales at post-treatment





Figure 168: Heartland forgiveness scales at post-treatment



0.5.4.4 Focused group therapy vs Wait-list control

Figure 169: Symptom checklist-90 R: Global Severity Index at post-treatment




Figure 170: Symptom Checklist-90 R: Positive symptom distress index at post-treatment






Figure 171: Symptom Checklist-90 R: Positive Symptom Total at post-treatment



0.5.4.5 Group Therapy vs No contact control

Figure 172: IIP-32 scales at post-treatment



O.5.5 ADHD

O.5.5.1 MPH vs Placebo

Figure 173: Conner Adult ADHD rating scale - Observer:Screening Version (CAARS-OSV) at post-treatment (52 weeks)




Figure 174: Conner Adult ADHD rating scale - Observer:Screening version (CAARS-OSV) at 3-years follow-up





Figure 175: Number of participants with drug negative urine at post-treatment



O.5.6 Antisocial personality disorders

O.5.6.1 Tiagabine vs Placebo

Figure 176: Aggressive response at post-treatment




Figure 177: Number of subjects with adverse effects at post-treatment



0.5.7 Severe Mental Illness

0.5.7.1 IM Paliperidone vs Oral Antipsychotics for schizophrenia

Figure 178: First-time treatment failure at post-treatment





Figure 179: Incidence of prolactin-related side-effects at post-treatment



0.5.7.2 The Citizenship Project vs TAU

Figure 180: Change in overall quality of life at post-treatment




Figure 181: Change in number of all convictions at post-treatment




Figure 182: Change in alcohol composite ratio at post-treatment




Figure 183: Change in brief psychiatric rating scale: withdrawal symptoms at post-treatment





Figure 184: Change in addiction severity index: drug index at post-treatment



0.5.7.3 IPS vs Peer Support

Figure 185: Competitive job placement




Figure 186: Number of hospitalizations





Figure 187: Number of days being hospitalized



O.5.8 Uncategorized mental health disorders

O.5.8.1 Parenting from inside (PFI) vs TAU

Figure 188: Parenting Stress Index at post-treatment




Figure 189: Parenting alliance at post-treatment





Figure 190: Brief Symptom Inventory (BSI): Total at post-treatment



O.5.8.2 Music therapy vs Standard care for mental health disorders

Figure 191: State and Trait Anxiety Inventory – State at post-treatment




Figure 192: State and Trait Anxiety Inventory – Trait at post-treatment




Figure 193: Brief Symptom inventory (BSI): Total at post-treatment




Figure 194: Rosenberg self-esteem inventory at post-treatment





Figure 195: Texas social behaviour inventory at post-treatment



0.5.8.3 Music therapy vs Wait-list control for antisocial personality disorders

Figure 196: ASP-1: Change in self-management of psychiatric symptoms at post-treatment




Figure 197: ASP-4: Change in self-management of assaultive symptoms at post-treatment




Figure 198: ASP-9: Change in interpersonal skills at post-treatment




Figure 199: Change in social dysfunction and aggression scales at post-treatment





Figure 200: FP40: Change in positive coping skills at post-treatment



O.6 Interventions for paraphilic disorders

O.6.1 MPA + psych intervention vs psych intervention only at post-treatment

Figure 201: Reduced anomalous desires




Figure 202: Repetition/persistence of anomalous behaviour





Figure 203: Drop out



O.6.2 MPA only vs psych intervention only at post-treatment

Figure 204: Reduced anomalous desires





Figure 205: Reduced anomalous behaviour



O.6.3 Psychoeducational interventions, principally CBT-informed psychoeducation (including SOTP) versus treatment as usual, no treatment or waitlist control for paraphilic disorders

Figure 206: Cognitive distortions (ABCS: Children and Sex Questionnaire)




Figure 207: Sexual obsessions (RCTs)




Figure 208: Reconviction (any): CJS database; controlled non-randomised studies; longest follow-up available 2-7 years




Figure 209: Sexual reconviction: CJS database; controlled non-randomised studies; longest follow-up available [2-11 years]




Figure 210: Violent reconviction: CJS database; controlled non-randomised studies; longest follow-up available [3-11 years]





Figure 211: Revocation, breaches of the Sex Offender Register or probation violation (CJS database; controlled non-randomised studies; longest follow-up available [2-5 years])



0.6.4 Reintegration programmes versus treatment as usual for paraphilic disorders

Figure 212: Reconivction at 2- to 4-year follow-up (CJS database)




Figure 213: Sex offence reconivction at 3- or 4-year follow-up (CJS database)




Figure 214: Violent reconviction at 3 to 4 years follow-up (CJS database)





Figure 215: Reincarceration for a technical violation revocation or failure to comply with Sex Offender's Register (SOR) requirements at 2- or 4-year follow-up (CJS database)



O.6.5 Imaginal desensitization plus MPA versus MPA for paraphilic disorders

Figure 216: Anomalous desire





Figure 217: Adverse events



O.6.6 Imaginal desensitization versus covert sensitization for paraphilic disorders

Figure 218: Anomalous desire





Figure 219: Loss to follow up



0.7 Service delivery models

0.7.1 Street Triage (Before versus After)

Figure 220: Total s136 detentions per 100,000





Figure 221: Number of s136 detentions in custody



Figure 222: Number of s136 detentions in hospital



0.7.2 Diversion Services

0.7.2.1 Before and After Diversion Services

Figure 223: Duration between remand assessment (days)





Figure 224: Days of total time on remand



0.7.2.2 Assessment versus No assessment at court

Figure 214: Proportions of prisoners on bail




Figure 215: Attendance at alcohol and drug treatment programmes





Figure 216: OPD attendance rates for those release on bail



Figure 217: Registration of care programmes (CPA) and supervision registration (SR)



0.7.2.3 Court Diversion vs Community Diversion

Figure 225: Rate of re-incarceration in two years after index discharge




Figure 226: 100% attendance rate of appointments



Figure 227: Number of days in hospital





Figure 228: Number of diverted participants with no mental health disorders



O.7.3 Patient Navigation Intervention versus facilitated enrolment (at 26-weeks follow-up)

Figure 229: Number of participants who used drugs




Figure 230: Number of participants who used alcohol to intoxication






Figure 231: Average days when mental health was not good in the last 30 days



O.7.4 Neighbourhood outreach (Before versus After)

Figure 232: Proportion of crime contacts with policing team escalated to court



O.7.5 Drug Rehabilitation Program versus TAU

Figure 233: MAP total scores




Figure 234: HoNOS total scores





Figure 235: Overall satisfaction



O.7.6 Case management

O.7.6.1 Case management vs TAU for substance misuse disorders

Figure 236: Re-arrest at post-treatment and 3-months follow-up




Figure 237: Reconviction at post-treatment





Figure 238: Re-incarceration

i) At post-treatment and 3-months follow-up



ii) At 12-months follow-up




Figure 239: Number of days jailed in past 6 months (12-months follow-up)




Figure 240: Drug related crimes in past 6 months (12-months follow-up)




Figure 241: Drug related crime activity during treatment (12-months follow-up)





Figure 242: Self-reported alcohol use

i) During treatment and post-treatment



ii) 12-months follow-up





Figure 243: Self-reported drug use

i) During treatment (marijuana or hard drugs) or post-treatment



ii) 12-months follow-up




Figure 244: Injection drug use (post-treatment)





Figure 245: Abstinence



0.7.6.2 Case management vs active intervention for substance misuse disorders

Figure 246: Remained in treatment for 6 months




Figure 247: Re-arrest at post-treatment and 3-months follow-up




Figure 248: Rearrest for drug crime (3 months follow-up)



Figure 249: Reconviction at post-treatment and 3-months follow-up




Figure 250: Re-incarceration at post-treatment and 3-months follow-up




Figure 251: Any self-reported drug use (3-months follow-up)





Figure 252: Positive hair test (3-months follow-up)



O.7.6.3 Assertive Community Treatment vs TAU for substance misuse disorders

Figure 253: Urine test positive for drug use during treatment




Figure 254: Self-reported injection drug use during treatment




Figure 255: Self-reported drug use during treatment





Figure 256: Re-incarceration during treatment



O.7.6.4 Case management vs TAU for mental health disorders other than substance misuse

Figure 257: Service utilization at post-treatment




Figure 258: Rate of re-offending at post-treatment




Figure 259: Number of days in jail (up to 24-months follow-up)





Figure 260: Quality of Life at post-treatment



O.7.7 Drug court

O.7.7.1 Drug court vs TAU

Figure 261: Days of substance misuse (12 months follow-up)





Figure 262: Re-arrest (12-month follow-up)



Figure 263: Maximum Crime Seriousness Scale (12-months follow-up)



O.7.7.2 Drug court vs active intervention

At post-treatment

Figure 264: Removed from treatment due to unsatisfactory progress




Figure 265: Addiction Severity Index (ASI): alcohol composite scores




Figure 266: Addiction severity index (ASI): drug composite score




Figure 267: Number of sanctions during treatment




Figure 268: Number of sanctions during treatment resulting in jail detention




Figure 269: Reincarceration during treatment




Figure 270: Urine test positive for drugs (post-treatment)



0.7.8 Opioid substitution therapy

0.7.8.1 Opioid substitution therapy + case management vs active intervention

Figure 271: Completed jail treatment




Figure 272: Urine test positive for cocaine




Figure 273: Urine test positive for opioids




Figure 274: Days of substance use (12-month follow-up)




Figure 275: Self-reported drug use in past 30 days (6-months follow-up)




Figure 276: Drug overdose at 6-months and 12-months follow-up




Figure 277: Re-arrest at 6-months and 12-months follow-up





Figure 278: Self-reported days of criminal activity (12 months follow-up)



O.7.9 Automated Telephony (AT) with feedback versus AT alone

Figure 279: Change in Arnetz and Hasson stress questionnaires (AHSS)




Figure 280: Change in symptom checklist-8D (SCL-8D)




Figure 281: Change in daily stressor assessment




Figure 282: Alcohol urge questionnaires: reduction in alcohol urge




Figure 283: Alcohol urge questionnaires: reduction in alcohol use




Figure 284: Alcohol urge questionnaires: reduction in drug urge





Figure 285: Alcohol urge questionnaires: reduction in drug use



O.7.10 IDDT versus TAU

Figure 286: Number of days in hospital




Figure 287: Rate of crisis visits






Figure 288: Rate of outpatient medication services



O.7.11 Housing First versus TAU

Figure 289: Any offence



O.7.12 TIMA versus TAU

Figure 290: Bipolar Disorder Symptom Scale (BDSS)





Figure 291: Brief Psychiatric Rating Scale (BPRS)



O.7.13 Service Brokerage Intervention versus TAU

Figure 292: Number of participants in contact with MH services





Figure 293: Number of participants who have seen GP




Figure 294: Number of participants who attended alcohol or drug service



O.7.14 Therapeutic communities

O.7.14.1 Therapeutic community versus waitlist control

Figure 295: Days until re-incarceration



O.7.14.2 Therapeutic community versus active intervention

Figure 296: Addiction Severity Index (ASI-6): alcohol composite score




Figure 297: Addiction Severity Index (ASI-6): drug composite score




Figure 298: Alcohol use at follow-up




Figure 299: Frequency of alcohol use at follow-up




Figure 300: Frequency of drug use at follow-up




Figure 301: Drug use at follow-up




Figure 302: Re-arrest at follow-up




Figure 303: Re-incarceration at follow-up




Figure 304: Self-reported criminal activity (any) at follow-up





Figure 305: Self-reported criminal activity (Drugs) at follow-up



O.7.14.3 Modified therapeutic community versus psychoeducation

Figure 306: Substance use (12 month follow-up)




Figure 307: Alcohol use (12 month follow-up)




Figure 308: Drug use (12 month follow-up)




Figure 309: Criminal activity (12 month follow-up)





Figure 310: Re-incarceration (12 month follow-up)



Figure 311: Alcohol or drug offences (12 month follow-up)



0.7.14.4 Enhanced therapeutic community versus standard therapeutic community

At post-treatment

Figure 312: Engagement with treatment





Figure 313: Negative mood (rated by counsellors)



0.7.14.5 Gender-responsive therapeutic community versus standard therapeutic community

Figure 314: Addiction Severity Index (ASI-6): alcohol composite score




Figure 315: Addiction Severity Index (ASI-6): psychological composite score




Figure 316: Addiction Severity Index (ASI-6): drug composite score




Figure 317: Addiction Severity Index (ASI-6): family composite score




Figure 318: Participated in after-care upon release




Figure 319: Months spent in after-care




Figure 320: Disciplinary removal from first residential placement post-release



Figure 321: Re-incarceration (12 month follow-up)




Figure 322: Voluntarily dropped out from first residential placement post-release





Figure 323: Months until re-incarceration



0.7.14.6 Gender-specific therapeutic community versus psychoeducation

Figure 324: Beck Depression Inventory (BDI) total score at post-treatment




Figure 325: Brief Symptom Inventory (BSI) total score at post-treatment




Figure 326: Post-traumatic Symptom Severity Scale (PSS) at post-treatment




Figure 327: Self-reported criminal activity (Any)




Figure 328: Self-reported criminal activity (Drug)




Figure 329: Self-reported criminal activity (Sexual)




Figure 330: Receiving substance abuse treatment at follow-up




Figure 331: Receiving mental health treatment at follow-up




Figure 332: Alcohol use at follow-up




Figure 333: Frequency of drug use




Figure 334: Self-reported drug use




Figure 335: Re-arrest at follow-up





Figure 336: Re-incarceration at follow-up



O.7.14.7 Re-entry modified therapeutic community versus treatment as usual

Figure 337: Re-incarceration at 12-month follow-up




Figure 338: Criminal activity



Figure 339: Alcohol/drug offences

